Resolution No. 6/08-4

ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES

VACCINES FOR CHILDREN PROGRAM

VACCINES TO PREVENT POLIOMYELITIS

The purpose of this resolution is to revise the previous resolution to incorporate the use of a pentavalent vaccine: 
diphtheria and tetanus toxoids, acellular pertussis, haemophilus influenza type b, and polio vaccines and a quadravalent vaccine: 
diphtheria and tetanus toxoids, acellular pertussis, and polio vaccines.
VFC resolution 2/03-3 is repealed and replaced by the following:  
Eligible Groups 
Children who are 6 weeks of age through 18 years.  DTaP-Hep B-IPV (PEDIARIX®) combination vaccine is approved for children 
=6 weeks to <7 years of age.  DTaP-Hib-IPV (Pentacel®) combination vaccine
is approved for children =6 weeks to <5 years of age.  DTaP-IPV (Kinrix™)combination vaccine is approved for the booster dose for 
children 
4 years to <7 years of age.  The use of brand names is not meant to preclude the use of other comparable licensed vaccines. 

Recommended Schedule for Polio Vaccines

       Dose	   	Age	  
       Primary 1	2 months
       Primary 2	4 months
       Primary 3	6-18 months
       Booster		4-6 years 
       
Dosage Intervals for Vaccination for Polio Containing Vaccines 
(Table)

Vaccine:IPV*
Minimum Age: 6 weeks
Dose 1 to 2: 4 weeks
Minimum interval between doses-
Dose 2 to 3: 4 weeks
Dose 3 to 4: 6 months



Vaccine: DTaP-HepB-IPV† 
Minimum Age: 6 weeks
Dose 1 to 2: 4 week
Minimum interval between doses-
Dose 2 to 3: 8 weeks
Vaccine:DTaP-Hib-IPV
Minimum Age: 6 weeks
Dose 1 to 2: 4 weeks
Minimum interval between doses-
Dose 2 to 3: 4 weeks
Dose 3 to 4:6 months
Vaccine: DTaP-IPV?
Minimum Age: 4 years
Dose 3 to 4: 6 months

*For children who receive an all-IPV series, a fourth dose is not necessary if the third dose was administered at age 4 years or older.

†The combined DTaP-HepB-IPV vaccine may be used when any component of the combination is indicated, and if the other 
components are not contraindicated. The combined DTaP-HepB-IPV vaccine is approved for the primary series only (Doses 1-3). 
For adequate immune response, the last dose of hepatitis B vaccine should be given at  =24 weeks of age and therefore this combination 
vaccine should not be administered as a complete primary series on an accelerated schedule at 4 week intervals for prevention of pertussis.  
The combined DTaP-HepB-IPV vaccine is not indicated for children >6 years of age.

The combined DTaP-Hib-IPV vaccine may be used when any component of the combination is indicated, and if the other components
are not contraindicated.  The combined DTaP-Hib-IPV vaccine is approved for the primary series and first booster dose (Doses 1-4).
The combined DTaP-Hib-IPV vaccine is not indicated for children 5 years of age and older.

The combined DTaP-IPV vaccine may be used when any component of the combination is indicated, and if the other components are not 
contraindicated.  The combined DTaP-IPV vaccine is approved for the booster dose at age 4-6 years.	

Catch-Up Vaccination 
The ACIP recommends catch-up vaccination of previously unvaccinated children and adolescents.

Recommended Dosages
Refer to product package inserts.







Contraindications and Precautions


The following conditions are contraindications to the administration of IPV vaccine: 
1.Allergy to vaccine components 
Persons who have had anaphylactic reactions to topically or systemically administered streptomycin, neomycin or polymyxin
 B should not receive IPV.


The following condition is a precaution to the administration of inactivated polio vaccine (IPV): 
1. Moderate or severe illnesses with or without fever

2. Pregnancy 
It is prudent on theoretical grounds to avoid vaccinating pregnant women with IPV vaccine. However, if immediate protection against 
poliomyelitis is needed, IPV may be administered. 

Adopted and Effective: June 26, 2008

























This document can be found on the CDC website at:
http://www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/0608polio.txt